Previous 10 | Next 10 |
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and ...
CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that new data from the vopratelimab ICONIC trial, on the...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose slightly last week from 3,759.2 points on Monday’s (December 2) open to 3,763.81 points as of 11:30 a.m. EST on Friday (December 6). On Tuesday (December 3), Cara Therapeutics (NASDAQ: CARA ) released results from a Phase 2 cli...
Gainers: Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a bit of a rocky week, but managed to stay in the green over the course of the trading period. The index opened last Monday (November 11) at 3,459.2 points before reaching 3,492.46 points as of 1:33 p.m. EST on Friday (November 15)...
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Jounce Therapeutics, Inc. (JNCE) Q3 2019 Earnings Conference Call November 07, 2019 08:00 AM ET Company Participants Komal Joshi - Investor Relations Rich Murray - Chief Executive Officer & President Beth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer ...
Jounce Therapeutics (NASDAQ: JNCE ) Q3 results : More news on: Jounce Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Jounce Therapeutics (NASDAQ: JNCE ): Q3 GAAP EPS of $2.90 beats by $0.66 . More news on: Jounce Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash burn guidance reduced - - Company to host conference call and webcast today at 8:00 A...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...